NCT00132379已完成1 期
An Open-label, Phase I, Dose-escalation Study of ABR-217620 in Combination With Docetaxel in Patients With Advanced Non-small Cell Lung Cancer (NSCLC)
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 13
- 试验地点
- 4
- 主要终点
- Side effect profile (based on blood pressure, body temperature, and laboratory tests)
研究概览
简要总结
The drug ABR-217620 is a combination of two proteins, one that recognizes tumor cells and one that triggers an attack on the tumor cells by activating some white blood cells belonging to the body's normal immune system. In animals, this results in an accumulation of white blood cells in the cancer that can fight the cancer. This study will test how much of the drug, in combination with docetaxel (an approved drug for treating non-small cell lung cancer [NSCLC]), can be given to patients with NSCLC without causing unacceptable side effects.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients with histologically or cytologically confirmed advanced NSCLC who have progressed on first line platin-based therapy or have failed on other treatment regimens or declined standard regimen.
- •ECOG performance status 0 or
- •Adequate bone marrow function: absolute neutrophil count greater than or equal to 1500/mm3; WBC greater than or equal to 3000/mm3; platelets greater than or equal to 100,000/mm3; and hemoglobin greater than or equal to 10 g/dL.
- •Adequate renal function: creatinine less than or equal to 1.5 x upper limit of normal (ULN).
- •Adequate hepatic function: bilirubin less than ULN; and SGOT (AST) and SGPT (ALT) to less than 1.5 x ULN concomitant with alkaline phosphatase (ALP) less than 2.5 ULN.
排除标准
- •Female patients who are pregnant or nursing or planning to become pregnant during the study. Fertile, sexually active women not willing to practice reliable contraception. Male patients with partners of childbearing potential not using acceptable contraceptive method.
- •A serious uncontrolled medical disorder or active infection including unexplained fever (temperature greater than 100.5 degrees Fahrenheit or 38.1 degrees Celsius) that would impair the patient's ability to receive study treatment.
- •Any concurrent malignancy, except for the following malignancies that may be included: non-melanoma skin cancer; cervical cancer in situ; ductal carcinoma in situ (DCIS) or lobular carcinoma in situ (LCIS) of breast; or past history of prostate cancer without clinical evidence of disease (includes patients receiving hormonal therapy).
- •History of brain metastases, unless stable for more than 4 weeks, and not requiring steroid therapy and without clinical symptoms of brain metastases.
- •Significant symptomatic cardiac disease including history (within past 6 months) or current unstable angina, congestive heart failure, or myocardial infarction; or patients with uncontrolled hypertension, or hypertension requiring treatment with more than 2 drugs.
- •History of or current arrhythmias requiring treatment, except for non-specific, asymptomatic ST-T wave changes or extrasystoles.
- •Seizure disorder requiring therapy.
- •Treatment with beta-blockers, including topical therapy for glaucoma, during the 6-day treatment period (5-day treatment + 1 day in-patient follow-up), and within 5 days before start of ABR-217620 treatment.
- •Simultaneous participation in any other investigational drug study or participation in a study less than 4 weeks before start of study treatment.
- •Treatment with systemic or inhaled corticosteroids within 2 weeks before start of treatment.
- •Treatment with anticoagulants, except when used to maintain the patency of a central venous line.
- •Active autoimmune disease requiring therapy or any history of systemic lupus erythematosus or rheumatoid arthritis.
- •Concurrent biological response modifiers (within 3 weeks of study entry) except for any type of erythropoetin.
- •Chemo/radio/immunotherapy less than 4 weeks (6 weeks for mitomycin C and nitrosoureas) before start of treatment.
- •Known allergy or hypersensitivity reactions to aminoglycosides (e.g., kanamycin).
- •Known allergy or hypersensitivity reactions to docetaxel or other drugs formulated with polysorbate
- •Previous exposure to murine monoclonal antibody (with human anti-mouse antibody [HAMA] titer above detection limit at baseline) or known hypersensitivity to murine proteins.
- •Major surgery within 3 weeks.
- •Known history of HIV infection.
- •Known chronic hepatitis B or C.
研究组 & 干预措施
1
Experimental
干预措施: ABR-217620 (Drug)
1
Experimental
干预措施: docetaxel (Drug)
结局指标
主要结局
Side effect profile (based on blood pressure, body temperature, and laboratory tests)
时间窗: Day 56 (Day 115 if undergo cycles 3/4)
次要结局
- Pharmacokinetic parameters(Days 1 and 4 of cycles 1 and 2)
- Immunological response(Day 56 (Day 115 if undergo cycles 3/4))
- Time to progression and Survival(Followed for up to 1 year)
- Changes in anti-SEA/E-120 levels(Day 56 (Day 115 if undergo cycles 3/4))
- Objective response rate(Day 56 (Day 115 if undergo cycles 3/4))
研究者
研究点 (4)
Loading locations...
相似试验
已完成
1 期
ABR-217620 in Patients With Advanced Non-Small Cell Lung Cancer, Renal Clear Cell Carcinoma or Pancreatic CancerNon-Small-Cell Lung CarcinomaPancreatic CancerRenal Cell CarcinomaNCT00056537Active Biotech AB44
已完成
1 期
A Study of BR101 Injection Alone in Subjects With Advanced Solid TumorsAdvanced Solid TumorNCT06001580BioRay Pharmaceutical Co., Ltd.15
已完成
1 期
Trial of MEK Inhibitor and PI3K/mTOR Inhibitor in Subjects With Locally Advanced or Metastatic Solid TumorsLocally Advanced Solid TumorMetastatic Solid TumorNon Small Cell Lung CancerBreast CancerColorectal CancerMelanomaNCT01390818EMD Serono146
尚未招募
1 期
A Study of B1962, a PD-L1/VEGF Bispecific Antibody Fusion Protein, for Advanced Solid TumorsNeoplasms MalignantNCT05650385Tasly Biopharmaceuticals Co., Ltd.68
招募中
1 期
GM103 Intratumoral Injection in Patients With Locally Advanced, Unresectable, Refractory and/or Metastatic Solid TumorsHead and Neck CancerMalignant MelanomaColorectal CancerCervical CancerRenal Cell CarcinomaBreast CancerNCT06265025GeneMedicine Co., Ltd.125